Isomyosamine

Isomyosamine, also known as MyMD-1 or MYMD-1, is a synthetic derivative of tobacco plant alkaloids being developed as a metabolic- and immunomodulator by MyMD Pharmaceuticals. To date, isomyosamine has been shown to suppress the production of IFN-γ, IL-2, IL-10, and TNF-α, and decrease the severity of experimental thyroiditis in a murine model.^[1] Trials in humans are being planned, and some are underway, examining the potential benefits of isomyosamine in autoimmune diseases such as rheumatoid arthritis, and in sarcopenia and frailty.^[2]

Isomyosamine

Identifiers
CAS Number	53844-46-5
3D model (JSmol)	Interactive image
ChemSpider	9461533
PubChem CID	11286546
UNII	3A50Y1J4LP
CompTox Dashboard (EPA)	DTXSID80461155
InChI InChI=1S/C9H10N2/c1-3-8(7-10-5-1)9-4-2-6-11-9/h1,3,5-7,9H,2,4H2 Key: GXTVPHUMJMZDSF-UHFFFAOYSA-N
SMILES C1CC(N=C1)C2=CN=CC=C2
Properties
Chemical formula	C9H10N2
Molar mass	146.193 g·mol−1
Related compounds
Related compounds	Myosmine Nicotine
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

MyMD Pharmaceuticals claim that MYMD-1 is not immunosuppressive, and thus should not be associated with the dangerous side effects such as infections that are seen in currently used TNF-α inhibitors such as adalimumab.^[3] While it is true that there currently is no evidence of immunosuppression in isomyosamine recipients, this has not yet been tested in large clinical trials.^{[citation needed]}

Scientific studies

Preclinical studies

One preliminary murine study comparing isomyosamine to rapamycin, the best-characterised drug slowing the progression of aging, reported an increase in lifespan in the isomyosamine cohort, indicating anti-aging activity. Isomyosamine's anti-proliferative effects were similar to those of rapamycin.^[4]

Clinical trials

A phase I randomised double-blind placebo-controlled trial on healthy volunteers examining the safety and pharmacokinetic properties of different amounts of isomyosamine found no serious adverse events, but 3 cases of mild dysgeusia in the highest-dose (600 mg) cohort. A preliminary decrease in TNF-α levels was reported in the lowest-dose (150 mg) cohort, but not in the placebo cohort.^[5]